Antiaggregation and gastroprotective drugs

Česká verzia

Authors: M. Janotka; V. Zdráhalová; P. Neužil
Authors place of work: Nemocnice Na Homolce, Praha ; Kardiologické oddělení ; Primář: doc. MUDr. Petr Neužil, CSc., FESC. ; Kardiovaskulární centrum
Published in the journal: Prakt. Lék. 2010; 90(11): 640-645
Category: Reviews

Summary

The introduction of this review focuses on the indication of gastroprotective therapy for patients taking antiaggregation and anticoagulation drugs. The review goes on to discuss the clinical results of the drug interaction with this combined therapy. In daily clinical practice physicians indicate gastroprotective therapy mainly intuitively. The Czech gastroenterological society, and Czech and European cardiology societies, do not provide clear guidelines for these indications. In 2008 the American Heart Association and American society of Gastroenterology released recommendations by a consensus of experts for the possibility of reducing the increased risk of gastrointestinal bleeding that occurs with non-steroids and antiaggregation therapy.

Key words:
antiaggregation therapy, NSAID, proton pump inhibitors.

Zdroje

1. Bhatt, D.L., Scheiman, J., Abraham, N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology task force on clinical expert consensus documents. Circulation 2008, 118, p. 1894-1909.

2. Silverstein, F.E., Faich, G., Goldstein, J.L. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284, p. 1247-1255.

3. de Abajo, F.J., Garcia-Rodriguez, L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin. Pharmacol. 2001, 1, p. 1.

4. Kelly, J.P. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348, p. 1413-1416.

5. Weil, J., Colin-Jones, D., Langman, M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310, p. 827-830.

6. Derry, S., Loke, Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000, 321, p. 1183-1187.

7. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324, p. 71–86.

8. Peters, R.J., Mehta, S.R. Fox, K.A. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108, p. 1682–1687.

9. Mehta, S.R., Tanguay, J.F., Eikelboom, J.W. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 2010, DOI:10.1016/S0140-6736(10) 61088-4.

10. Hallas, J., Dall, M., Andries, A. et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006, 333, p. 726.

11. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348, p.1329-1339.

12. Lanas, A., Garcia-Rodriguez, L.A., Arroyo, M.T. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase- 2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55, p.1731-1738.

13. Andreotti, F., Testa, L., Biondi-Zoccai, G.G. Crea, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur. Heart J. 2006, 27, p. 519-526.

14. Anand, S., Yusuf, S., Xie, C. et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease- WAVE trial. N. Engl. J. Med. 2007, 357, p. 217-227.

15. Rosini, R., Musumeci, G., Lettieri, C. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am. J. Cardiol. 2008, 102, p. 1618-1623.

16. Lanas, A., Scheiman, J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 2007, 23, p. 163-173.

17. Chan, F.K. Long-term incidence of ulcer bleeding with low-dose aspirin after eradication of H pylori: a 4-year prospective cohort study (abstr). Gastroenterology 2005, 128, A133.

18. Chan, F.K., Chung, S.C., Suen, B.Y. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001, 344, p. 967-973.

19. Lai, K.C., Lam, S.K., Chu, K.M. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002, 346, p. 2033-2038.

20. Sung, J., Lau, J., Ching, J. et al. Can aspirin be reintroduced with PPI inhibitor INFUSION after endoscopic hemostatis: a double-blinded randomized controlled trial. Gastroenterology 2008, 130, A44.

21. Hurlen, M., Abdelnoor, M., Smith, P. et al. Warfarin, aspirin or both after myocardial infarction. N. Engl. J. Med. 2002, 347, p. 969-974.

22. Silverstein, F.E., Graham, D.Y., Senior, J.R. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1995, 123, p. 241-249.

23. Simon, T., Verstuyft, C., Mary-Krause, M. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009, 360, p. 363-375.

24. Mega, J.L., Close, S.L., Wiviott, S.D. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360, p. 354-362.

25. Collet, J.P., Hulot, J.S., Pena, A. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373, p. 309-317.

26. Bhatt, D.L. COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting, September 2009, San Francisco, USA.

27. Dunn, S.P., Macaulay, T.E., Brennan, D.M. et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008, 118, S 815.

28. Aubert, R.E., Epstein, R.S., Teagarden, J.R. et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 2008, 118, S 815.

29. Stanek, E.J., Aubert, R.E., Flockhart, D.A. et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopiodogrel following coronary stenting: The Clopidogrel Medco Outcomes. Dostupné z scaiscientificsessions.org/wednesdaymay6/LBCT_Stanek_Clopidogrel-PPI_SCAI.ppt.

30. Juurlink, D.N., Gomes, T, Ko, D.T. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180, p. 713-718.

31. Ho, P.M., Maddox, T.M., Wang, L. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301, p. 937-944.

32. O’Donoghue, M.L., Braunwal, E., Antman, E.M. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374, p. 989-997.

33. Gilard, M., Arnaud, B., Le Gal, G. et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost. 2006, 4, p. 2508-2509 (Letter).

34. Gilard, M., Arnaud, B., Cornily, J.C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized,double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008, 51, p. 256-260.

35. Small, D.S., Farid, N.A., Payne, C.D. et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 2008, 48, p. 475-484.

36. Siller-Matula, J.M., Spiel, A.O., Lang, I.M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009, 157, 148.e1-5.

37. Sibbing, D., Morath, T., Stegherr, J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 2009, 101, p. 714-719.

38. Laine, L., Hennekens, Ch. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 105: 34-41; advance online publication, November 10, 2009; doi:10.1038/ajg.2009.638.

39. Simon, T., Mulak, G., Bataille, V., Danchin, N. Genetic determinants of response to Clopidogrel and cardiovascular events. N. Engl. J. Med. 2009, 360, p. 363-375.

40. Wiviott, S.D., Trenk, D., Frelinger, A.L. III. Prasugrel versus Clopidogrel in patients with acute coronary syndrome. N. Engl. J. Med. 2007, 357, p. 2001-2015.

41. Ramirez, J.F., Selzer, F., Chakaprani, R. Proton pump inhibitor and clopidogrel interaction, JACC 2009, 53 (Suppl 1), A27

42. Johnson, D.A. Upper GI risks of NSAIDs and antiplatelet agents. Rev. Cardiovasc. Med. 2005, 6 (suppl 4), S15–22.

43. Rassen, J.A., Choudhry, N.K., Avorn, J., Schneeweiss, S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120, p. 2322–2329.

44. Wallace, J.L., McKnight, W., Reuter, B.K. et al. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000, 119, p. 706-714.

45. Bombardier, C., Laine, L., Reicin, A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343, p. 1520-1528.

46. Abraham, N.S. Hartman, C. Castillo, D. et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am. J. Gastroenterol. 2008, 103, p. 323–332.

47. Lai, K.C., Chu, K.M. Hui, W.M. et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin. Gastroenterol. Hepatol. 2006, 4, p. 860-865.

48. Sung, J., Lau, J., Ching, J. et al. Can aspirin be reintroduced with PPI inhibitor infusion after endoscopic hemostatis: a double-blinded randomized controlled trial (abstr). Gastroenterology 2008, 130: A44.

49. Mega, J.L., Close, S.L., Wiviot, S.D. et al. Cytochrome P450 genetic polymorphism and the response to prasugrel: relationship to pharmakinetic, pharmadynamic and clinical outcomes. Circulation 2009, 119, p. 2553-2560.